Abstract:Abstract Introduction In the absence of reversible etiology, central sleep apnea (CSA) may be treated with positive airway pressure (CPAP or BPAP), adaptive servo-ventilation, or supplemental oxygen. In 2017, a transvenous phrenic nerve stimulator (PNS), the remedē SystemTM, was FDA-approved for moderate-to-severe CSA. Five-year outcomes data confirmed the device’s sustained efficacy, with improvements in symptoms, apnea-hypopnea index(AHI), and central apnea index(CAI). While the device effectively treats CSA, unrecognized upper airway obstruction may hinder clinical success. This case report describes a patient whose polysomnography (PSG) suggested candidacy for PNS; however, his airway collapsibility led to severe obstructive sleep apnea(OSA), unmasked after PNS implantation. Report of case(s) Our patient is a 74-year-old with longstanding severe CSA and chronic insomnia. He has a history of spasmodic dysphonia status post recurrent laryngeal nerve ablation. His unilateral vocal fold paralysis was followed by injection medialization for voice augmentation. He is also an asymptomatic carrier of myotonic dystrophy(MD), identified after his grandchild was diagnosed with MD. He presented to our institution for daytime sleepiness, disrupted sleep and snoring with complaints of PAP intolerance. PSG revealed an AHI4% of 49.1 events/hour with 0 obstructive apneas, 89 central apneas, and 53 unclassified hypopneas. Transthoracic echocardiogram was unremarkable. Pulmonary function tests were normal without evidence of neuromuscular weakness or extrathoracic obstruction. He underwent PNS implantation. Postoperatively, the patient continued endorsing unrefreshed sleep. His PNS titration study demonstrated prolonged flow limitation and an AHI4% of 35.2 events/hour with frequent obstructive events. He is now using a mandibular advancement device (MAD) with the PNS. Conclusion This case highlights the impact of upper airway collapsibility on PNS treatment response. Although our patient’s history may have indicated greater susceptibility to airway collapse, preoperative PSG did not reveal unequivocal OSA. However, frequent obstructive hypopneas were unmasked after PNS implantation. This patient’s upper airway collapse was underrepresented on PSG, and increased negative intrathoracic pressure during the PNS titration may have worsened the severity. Since differentiating central from obstructive hypopneas can be challenging, PNS may not be ideal for CSA patients with increased hypopnea burdens. If OSA emerges postoperatively, adjuncts like MAD, CPAP, or hypoglossal nerve stimulation may stabilize the upper airway. Support (if any)

0993 A Senseless Sensing Lead: A Case Of Failed Sensing Lead In Hypoglossal Nerve Stimulator

Are There Hidden Adverse Events in Hypoglossal Nerve Stimulation: Comparing Social Media and a Federal Database

1200 Overstimulated: A Case of Hypoglossal Nerve Stimulator Over-titration

1160 Examining Criteria in Hypoglossal Nerve Stimulation: A Case Insight

1230 Management of Severe OSA with HGNS: Importance of In-Lab Sleep Studies for Accurate Assessment-bA Case Report

0590 Hypoglossal Nerve Stimulation for OSA – a Systematic Review of Adverse Events in Clinical Trials & Real-world-data

Hypoglossal nerve stimulation over-titration

1178 CASE REPORT – USE of WEARABLE OXIMETRY DEVICE to TITRATE HYPOGLOSSAL NERVE STIMULATION SETTINGS

0594 Novel Device to Simulate Hypoglossal Nerve Stimulation Response to Predict Surgical Success

0591 Improving Efficiency & Patient Outcomes Using Longitudinal Monitoring via a HSAT with Hypoglossal Nerve Stimulation

1188 Decreased Tolerance to Hypoglossal Nerve Stimulator After Cardioversion

Comparison of Home Sleep Devices and Sleep Study Testing in Hypoglossal Nerve Stimulation Patients

Case report of hypoglossal nerve stimulation therapy failure due to significant underlying central sleep apnea

1173 Unmasking Severe OSA After Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea

0597 Hypoglossal Nerve Stimulation Adherence Increasing Yearly

Minimally Invasive Hypoglossal Nerve Stimulator Enabled by ECG Sensor and WPT to Manage Obstructive Sleep Apnea

Upper Airway Stimulation for Children and Adolescents with Down Syndrome: Long‐Term Follow‐Up

1163 Central Sleep Apnea: A Possible Rare Adverse Effect of Vagus Nerve Stimulation

Misidentification of vagus nerve stimulator for intravenous access and other major adverse events

1229 Dual Neurostimulator Therapy for CSA and OSA in an Elderly Gentleman with Native Pacemaker

Impact of Hypoglossal Nerve Stimulation on Consumer Sleep Technology Metrics and Patient Symptoms